No quick redemption for GlaxoSmithKline’s $4B alliance with Merck KGaA as bispecific cancer drug flunks a second trial
GlaxoSmithKline’s $4 billion bispecific cancer drug alliance is taking another hit.
Just weeks after revealing a Phase III setback in non-small cell lung cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
